These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33669738)

  • 1. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
    Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
    Yuda GPWC; Hanif N; Hermawan A
    Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring epigenetic drugs as potential inhibitors of SARS-CoV-2 main protease: a docking and MD simulation study.
    Uzuner U; Akkus E; Kocak A; Çelik Uzuner S
    J Biomol Struct Dyn; 2024 Aug; 42(13):6892-6903. PubMed ID: 37458994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
    Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z
    Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
    Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of highly potent SARS-CoV-2 M
    Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
    Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
    Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
    Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M
    Hu Q; Zhang Y; Chen P; Zhang Y; Zhu G; Liu W; Wang C; Zheng S; Shen N; Wang H; Huang P; Ge G
    Chin J Nat Med; 2024 Sep; 22(9):797-807. PubMed ID: 39326974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by
    Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A
    J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
    Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
    J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Bung N; Krishnan SR; Bulusu G; Roy A
    Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764
    [No Abstract]   [Full Text] [Related]  

  • 19. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
    Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
    Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
    Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.